Quick answers
- What is Citric acid, gluconolactone and magnesium carbonate used for?
- The FDA-approved label (Renacidin, United-Guardian, Inc., December 17, 2019) says: “Renacidin is indicated for dissolution of bladder calculi of the struvite or apatite variety by local intermittent irrigation through a urethral catheter or cystostomy tube as an alternative or adjunct to surgical procedures. Renacidin is also indicated for use as an intermittent irrigating solution to prevent encrustations of indwelling urethral catheters and cystostomy tubes.” This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
- What are the side effects of Citric acid, gluconolactone and magnesium carbonate?
- The “Adverse Reactions” section of the FDA label (Renacidin, United-Guardian, Inc., December 17, 2019) begins: “The most common adverse reactions with use of Renacidin for dissolution of bladder calculi or prevention of encrustations of indwelling urethral catheters are “bladder irritability” and chemical cystitis, both reported to occur in approximately 3% of patients. A transient burning sensation in the bladder following Renacidin has been reported to occur in less than 1% of patients receiving Renacidin.” This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
- Does Citric acid, gluconolactone and magnesium carbonate have a boxed warning?
- No. None of the 1 FDA labels we found for this medicine has a boxed warning.
- Is there a shortage of Citric acid, gluconolactone and magnesium carbonate?
- No current shortage is listed by the FDA for the products of this medicine (FDA data from November 13, 2026).
- Has Citric acid, gluconolactone and magnesium carbonate been recalled?
- No recall linked to the products of this medicine appears in the FDA enforcement reports we use.
- Who makes Citric acid, gluconolactone and magnesium carbonate?
- 1 company lists prescription products of Citric acid, gluconolactone and magnesium carbonate in the FDA NDC Directory, including United-Guardian, Inc.
What Citric acid, gluconolactone and magnesium carbonate is used for
Quoted from the “Indications and Usage” section of the FDA-approved label.
Renacidin is indicated for dissolution of bladder calculi of the struvite or apatite variety by local intermittent irrigation through a urethral catheter or cystostomy tube as an alternative or adjunct to surgical procedures. Renacidin is also indicated for use as an intermittent irrigating solution to prevent encrustations of indwelling urethral catheters and cystostomy tubes.
— FDA label: Renacidin, United-Guardian, Inc., effective December 17, 2019. Read the full label on DailyMed →
Label quoted: the one for the most common form (solution, irrigation), Renacidin, United-Guardian, Inc.; it covers 1 product in the FDA NDC Directory. The side effects, interactions, dosage and pregnancy quotes below come from this same label.
This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
Boxed warning
A boxed warning (“black box”) is the FDA’s strongest warning on a drug label, for serious or life-threatening risks.
The label quoted above has no boxed warning.
Citric acid, gluconolactone and magnesium carbonate side effects
Quoted from the “Adverse Reactions” section of the FDA-approved label. Tell your doctor about any side effect that worries you.
The most common adverse reactions with use of Renacidin for dissolution of bladder calculi or prevention of encrustations of indwelling urethral catheters are “bladder irritability” and chemical cystitis, both reported to occur in approximately 3% of patients. A transient burning sensation in the bladder following Renacidin has been reported to occur in less than 1% of patients receiving Renacidin.
— FDA label: Renacidin, United-Guardian, Inc., effective December 17, 2019. Read the full label on DailyMed →
Citric acid, gluconolactone and magnesium carbonate dosage
Quoted from the “Dosage and Administration” section of the FDA-approved label. Your own dose is the one your doctor prescribes: do not change it on your own.
Renacidin for local irrigation within the lower urinary tract is available in single-use 30 mL containers. Prepare and Administer the Dose: Step 1: Inspect Renacidin visually for particulate matter and discoloration prior to administration. If particulate matter or discoloration are observed, do not administer. Step 2: Remove the plastic tab connected to the conical tip of the Renacidin container by twisting the plastic tab. See Figure 1.
Read more of this section
Figure 1 Step 3: Connect the conical tip of the Renacidin container to the end of the urethral catheter or cystostomy tube. See Figure 2. Figure 2 Step 4: Squeeze the Renacidin container to expel the entire contents into the urethral catheter or cystostomy tube. See Figure 3. Figure 3 For Dissolution of Bladder Calculi: Instill 30 mL (one container) of Renacidin into the bladder via a urethral catheter or cystostomy tube. Clamp the urethral catheter or cystostomy tube for 30 to 60 minutes. Release the clamp and drain the bladder. Repeat the instillation procedure 4 to 6 times a day. Monitor for dissolution of calculi. For Prevention of Encrustations in Urethral Catheters and Cystostomy Tubes: Instill 30 mL (one container) of Renacidin into the urethral catheter or cystostomy tube. Clamp the urethral catheter or cystostomy tube for 10 minutes. Remove the clamp and drain the bladder. Repeat the instillation procedure 3 times a day. Figure 1 Figure 2 Figure 3
— FDA label: Renacidin, United-Guardian, Inc., effective December 17, 2019. Read the full label on DailyMed →
Citric acid, gluconolactone and magnesium carbonate in pregnancy
Quoted from the pregnancy part of the FDA-approved label. Ask your doctor before you take any medicine while pregnant or planning a pregnancy.
Category C Animal reproduction studies have not been conducted with Renacidin. It is also not known whether Renacidin can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Renacidin should be given to a pregnant woman only if clearly needed.
— FDA label: Renacidin, United-Guardian, Inc., effective December 17, 2019. Read the full label on DailyMed →
Citric acid, gluconolactone and magnesium carbonate and breastfeeding
Quoted from the nursing mothers / lactation part of the FDA-approved label.
Magnesium is known to be excreted into human milk. It is not known whether Renacidin is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Renacidin is administered to a nursing woman.
— FDA label: Renacidin, United-Guardian, Inc., effective December 17, 2019. Read the full label on DailyMed →
When Citric acid, gluconolactone and magnesium carbonate should not be used
Quoted from the “Contraindications” section of the FDA-approved label.
Renacidin is contraindicated in the presence of demonstrable urinary tract extravasation.
— FDA label: Renacidin, United-Guardian, Inc., effective December 17, 2019. Read the full label on DailyMed →
Forms and how it is given
| Dosage forms | Solution |
|---|---|
| Route | Irrigation |
| Prescription products | 1 in the FDA NDC Directory |
| Brand names | Renacidin |
Companies that list this medicine
Labelers in the FDA NDC Directory: the company named on the package (maker or distributor), with the number of prescription products.
- United-Guardian, Inc.1 product
FDA approval history
- NDA: New Drug Application: how a new (usually brand-name) medicine is approved.
| Application | Sponsor | Approved | Later changes approved |
|---|---|---|---|
| NDA019481 RENACIDIN | United Guardian | October 2, 1990 | 10, latest December 16, 2015 2015: Manufacturing (CMC) · 2015: Labeling · 2014: Manufacturing (CMC) |
Shortage status
The FDA drug shortage list does not show these products.
Recalls
No recall linked to these products (by their NDC code) appears in the FDA enforcement reports.
Official identifiers
| RxCUI (RxNorm) | 1792396, 1792398 |
|---|---|
| SPL set ID of the quoted label | 13a9bbba-db21-4cba-991c-5d8afaf2ed74 |
| FDA labels (SPL) | 1 |
| FDA applications | NDA019481 |
| Active ingredients (FDA) | ANHYDROUS CITRIC ACID / GLUCONOLACTONE / MAGNESIUM CARBONATE |
Next steps
- Find a pharmacy near youAsk which price applies to you and whether your product is affected by a recall
- Latest FDA drug recallsAll medicines, newest first
- United-Guardian, Inc.Maker or distributor
- All prescription drugs A to ZSearch by generic, brand or Spanish name
Sources
- FDA-approved label on DailyMed (National Library of Medicine) — Renacidin, United-Guardian, Inc., effective December 17, 2019; via openFDA, FDA data exported November 13, 2026, retrieved November 14, 2026
- NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 13, 2026, retrieved November 14, 2026
- Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 13, 2026, retrieved November 14, 2026
- Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 10, 2026, retrieved November 14, 2026
- Drug shortages (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 13, 2026, retrieved November 14, 2026
openFDA data is provided by the FDA as is; it may be incomplete. Always rely on the label that comes with your medicine. FDA Enforcement Report search →